Healthcare Industry News: metabolic disease
News Release - May 1, 2007
Ilypsa Announces Promotion of Paul A. Stone to Senior Vice President, General Counsel and Chief Patent CounselSANTA CLARA, Calif.--(HSMN NewsFeed)--Ilypsa, Inc, a privately-held biopharmaceutical company pioneering novel non-absorbed drugs for renal disorders, today announced the promotion of Paul A. Stone to the position of Senior Vice President, General Counsel and Chief Patent Counsel.
"We are pleased to promote Paul to General Counsel in recognition of his instrumental role in directing all legal matters at Ilypsa, including development of our strategic patent position, over the past two years," said Jay Shepard, President and Chief Executive Officer of Ilypsa. "Paul's counsel has added great value to Ilypsa as we have grown from a company with unique opportunities and a powerful platform for discovering and advancing non-absorbed polymeric drugs into a company with five promising product candidates."
"I am honored to lead the legal effort at Ilypsa, particularly at this exciting time for the company with our lead product rapidly advancing towards Phase III clinical investigation," said Mr. Stone. "It has been very professionally and personally satisfying to work with Ilypsa's outstanding management team and employees."
Mr. Stone joined Ilypsa in April 2005 as Vice President, Intellectual Property and Chief Patent Counsel. In this role, he has been responsible for corporate, transactional and patent legal matters, with substantial contributions to Ilypsa's Series B financing, strategic licensing, and patent portfolio development efforts. Prior to Ilypsa, Mr. Stone was Vice President & Chief Patent Counsel at Symyx Technologies, Inc. which he joined in 1998. Earlier, Mr. Stone represented clients in the chemical, biotechnological and pharmaceutical arts as an associate with the intellectual property law firm of Senniger, Powers, Leavitt & Roedel in St. Louis, Missouri. Mr. Stone received his J.D. degree from the University of Wisconsin Law School and his B.S. degree in chemical engineering from the University of Wisconsin-Madison. Mr. Stone is also an adjunct professor at the Santa Clara University School of Law.
About Ilypsa, Inc.
Ilypsa, Inc. is a privately held biopharmaceutical company discovering and developing a pipeline of next-generation renal care pharmaceutical products. Pioneering the use of a proprietary high throughput discovery and development platform created and validated at Symyx Technologies, Inc. (NASDAQ:SMMX ), Ilypsa has rapidly created non-absorbed polymeric phosphate and potassium binder compounds to treat chronic kidney disease, and has additional programs in kidney, infectious and metabolic diseases. To date, Ilypsa has raised $46 million in a Series A and Series B round of financing. Investors include The Sprout Group, 5AM Ventures, US Venture Partners, Johnson & Johnson Development Corporation and Delphi Ventures. For more information, please visit www.ilypsa.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.